Silencing Kif2a induces apoptosis in squamous cell carcinoma of the oral tongue through inhibition of the PI3K/Akt signaling pathway

Molecular Medicine Reports

Volumn 9, Issue 1, 2014, Pages 273-278

  Wang, Ketao ^a   Lin, Changlong ^a   Wang, Chengqin ^b   Shao, Qianqian ^a   Gao, Wenjuan ^a   Song, Bingfeng ^a   Wang, Lei ^a   Song, Xiaobin ^a   Qu, Xun ^a   Wei, Fengcai ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Kinesin 13 family 2a; Phosphatidylinositol 3 kinase; Protein kinase B; Squamous cell carcinoma of the oral tongue

Indexed keywords

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KINESIN; MOUTH NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84893822832     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1804     Document Type: Article

References (17)

1. Ganem NJ and Compton DA: The KinI kinesin Kif2a is required for bipolar spindle assembly through a functional relationship with MCAK. J Cell Biol 166: 473-478, 2004.
2. Ganem NJ, Upton K and Compton DA: Efficient mitosis in human cells lacking poleward microtubule flux. Curr Biol 15: 1827-1832, 2005.
3. Wang CQ, Qu X, Zhang XY, et al: Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongue. Oral Oncol 46: 65-69, 2010.
4. Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929, 2005.
5. Brader S and Eccles SA: Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 90: 2-8, 2004.
6. Yen CC, Chen YJ, Lu KH, et al: Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction. Int J Oncol 23: 871-881, 2003.
7. Zhang G, Zhou X, Xue L, et al: Accumulation of cytoplasmic beta-catenin correlates with reduced expression of E-cadherin, but not with phosphorylated Akt in esophageal squamous cell carcinoma: immunohistochemical study. Pathol Int 55: 310-317, 2005.
8. Bian Y, Terse A, Du J, et al: Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res 69: 5918-5926, 2009.
9. Iamaroon A and Krisanaprakornkit S: Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol 45: e175-e179, 2009.
10. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
11. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208, 2004.
12. Liu Y, Chen L, Ko TC, Fields AP and Thompson EA: Evi1 is a survival factor which conveys resistance to both TGFbeta-and taxol-mediated cell death via PI3K/AKT. Oncogene 25: 3565-3575, 2006.
13. Li B, Cheung PY, Wang X, Tsao SW, Ling MT, Wong YC and Cheung AL: Id-1 activation of PI3K/Akt/NFκB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 28: 2313-2320, 2007.
14. Xin M and Deng X: Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 280: 1078l-10789, 2005.
15. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
16. Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005.
17. Zimmermann TS, Lee AC, Akinc A, et al: RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114, 2006.